| Abbott: Humira and MTX treatment gives cost savings | Posted on 18/06/2008 in Pharmaceutical Company Product News Abbott has announced the release of new data showing that treating active early rheumatoid arthritis patients with a combination of methotrexate (MTX) and Humira (adalimumab) results in indirect cost savings as a result of increased work productivity.
Savings of around 4,845 euros (3,842 pounds) were observed per patient per year compared to those treated with MTX alone.
These cost savings were attributed to the ability to gain or regain employment in 12 per cent of cases, a reduction in the number of workdays missed in nine per cent of patients and improved work performance in 79 per cent of cases.
A separate analysis showed joint damage in the early stages of rheumatoid arthritis to be a predictor of the ability of a patient to gain or retain employment, while the condition is noted to be the leading cause of work disability in Europe.
Ronald F. van Vollenhoven of the Karolinska University Hospital in Stockholm, said: "While rheumatoid arthritis is a progressive and chronic disease, patients may be able to continue productive work lives with the help of treatment options such as adalimumab."
Abbott recently announced new data from the phase III Atlas trial showing that Humira can reduce the signs and symptoms of ankylosing spondylitis.Other news stories from 18/06/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
